MedTrace Logo

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

NCT00804479 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2016-01-21

No results posted yet for this study

Summary

To determine the long-term consequences (8 years) of initiating patients with Parkinson's disease on either pramipexole or levodopa. We hypothesize that patients initiating therapy with pramipexole compared with levodopa will demonstrate less self-reported disability as measured by the Modified Schwab and England (S/E) scale 8 years after randomization.

Conditions

Interventions

OTHER

No intervention.

Sponsors & Collaborators

  • Pharmacia Corp. (Peapack, NJ)

    collaborator UNKNOWN

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2004-03-31
Completion
2004-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00804479 on ClinicalTrials.gov